Proceedings of the National Academy of Sciences of the United States of America · 2018
Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uhl George R, Martinez Maria J, Paik Paul, Sulima Agnieszka, Bi Guo-Hua, Iyer Malliga R, Gardner Eliot, Rice Kenner C, Xi Zheng-Xiong
Аннотация
Receptor-type protein tyrosine phosphatase D (PTPRD) is a neuronal cell-adhesion molecule/synaptic specifier that has been implicated in addiction vulnerability and stimulant reward by human genomewide association and mouse cocaine-conditioned place-preference data. However, there have been no reports of effects of reduced expression on cocaine self-administration. There have been no reports of PTPRD targeting by any small molecule. There are no data about behavioral effects of any PTPRD ligand. We now report (i) robust effects of heterozygous PTPRD KO on cocaine self-administration (These data substantially extend prior conditioned place-preference data and add to the rationale for PTPRD as a target for addiction therapeutics.); (ii) identification of 7-butoxy illudalic acid analog (7-BIA) as a small molecule that targets PTPRD and inhibits its phosphatase with some specificity; (iii) lack of toxicity when 7-BIA is administered to mice acutely or with repeated dosing; (iv) reduced cocaine-conditioned place preference when 7-BIA is administered before conditioning sessions; and (v) reductions in well-established cocaine self-administration when 7-BIA is administered before a session (in WT, not PTPRD heterozygous KOs). These results add to support for PTPRD as a target for medications to combat cocaine use disorders. 7-BIA provides a lead compound for addiction therapeutics.
Предметные рубрики MeSH
AnimalsCatheters, IndwellingCocaine-Related DisordersConditioning, PsychologicalCoumarinsDisease Models, AnimalGene Expression RegulationHumansInjections, IntravenousLigandsMiceMice, Inbred C57BLMice, KnockoutNarcotic AntagonistsNeuronsReceptor-Like Protein Tyrosine Phosphatases, Class 2RewardSelf AdministrationSignal TransductionSubstance Abuse, IntravenousToxicity Tests, AcuteToxicity Tests, Chronic